Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amlodipine
Amlodipine/Atorvastatin calcium · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Amlodipine Besylate/Benazepril HCl | EXPERIMENTAL | Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd. |
| Lotrel | ACTIVE_COMPARATOR | Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals |
| Name | Type | Description |
|---|---|---|
| Amlodipine Besylate/Benazepril HCl | DRUG | Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules |
Inclusion Criteria: * Subjects will provide written informed consent. * Subjects must be healthy adults within 18-45 years of age (inclusive). * Body mass index of ≥18 kg/m2 and ≤25 kg/m2, with body weight not less than 50 kg. * Subjects must be of normal health as determined by medical history and...
Amlodipine/Atorvastatin calcium is a small molecule drug candidate developed by Dr. Reddy's Laboratories Ltd (ticker RDY). It has been studied in Phase 1 clinical trials, with one completed trial and no active trials. The program has involved 50 total enrolled participants.
Amlodipine/Atorvastatin calcium targets CACNA1C, CACNA1S, CACNA1D, and CACNA1F. It is classified as a blocker. These calcium channel targets are associated with its mechanism of action as a small molecule therapeutic.
Amlodipine/Atorvastatin calcium is being developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. The company has conducted Phase 1 clinical testing of this small molecule candidate.
Amlodipine/Atorvastatin calcium is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are currently no active trials. The drug is investigational and has not been approved by the FDA.
Amlodipine/Atorvastatin calcium has been evaluated in two completed Phase 1 bioequivalence trials: NCT01506011 under fasting conditions and NCT01505998 under fed conditions. Both trials were conducted in India with healthy volunteers aged 18 years and older.